Correlation Between Sartorius Stedim and Carmat SA

Can any of the company-specific risk be diversified away by investing in both Sartorius Stedim and Carmat SA at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sartorius Stedim and Carmat SA into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sartorius Stedim Biotech and Carmat SA, you can compare the effects of market volatilities on Sartorius Stedim and Carmat SA and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sartorius Stedim with a short position of Carmat SA. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sartorius Stedim and Carmat SA.

Diversification Opportunities for Sartorius Stedim and Carmat SA

0.14

Correlation Coefficient

Sartorius Stedim  Carmat SA

Average diversification

The 3 months correlation between Sartorius and Carmat is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Sartorius Stedim Biotech and Carmat SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Carmat SA and Sartorius Stedim is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sartorius Stedim Biotech are associated (or correlated) with Carmat SA. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Carmat SA has no effect on the direction of Sartorius Stedim i.e., Sartorius Stedim and Carmat SA go up and down completely randomly.

Pair Corralation between Sartorius Stedim and Carmat SA

Assuming the 90 days trading horizon Sartorius Stedim Biotech is expected to generate 0.7 times more return on investment than Carmat SA. However, Sartorius Stedim Biotech is 1.44 times less risky than Carmat SA. It trades about 0.07 of its potential returns per unit of risk. Carmat SA is currently generating about -0.12 per unit of risk. If you would invest  15,035  in Sartorius Stedim Biotech on September 29, 2024 and sell it today you would earn a total of  3,390  from holding Sartorius Stedim Biotech or generate 22.55% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Sartorius Stedim Biotech  vs.  Carmat SA

Sartorius Stedim Biotech

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sartorius Stedim Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Sartorius Stedim is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders.

Carmat SA

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Carmat SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.

Pair Trading with Sartorius Stedim and Carmat SA

The main advantage of trading using opposite Sartorius Stedim and Carmat SA positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sartorius Stedim position performs unexpectedly, Carmat SA can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Carmat SA will offset losses from the drop in Carmat SA's long position.

The idea behind Sartorius Stedim Biotech and Carmat SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.